In vitro and in vivo suppression of growth of hepatocellular carcinoma cells by albendazole
Introduction
Albendazole a benzimidazole carbamate (methyl 5-propylthio-1H-benzimidazole-2-yl carbamate) is a broad spectrum antiparasitic which is used worldwide against a variety of parasites [1], [2]. Studies conducted on the mechanism of action of BZs have demonstrated that, by binding to tubulin, these drugs inhibit microtubule polymerization [3], [4], [5], [6]. Inhibitors of microtubule polymerization have been shown to exhibit experimentally and clinically, useful antitumor activity [7]. Consequently, the reported activity of BZs against human mammalian tubulin raises the question of whether these agents also possess anticancer properties. In 1985 Lacey and Watson reported the activity of BZs against mouse L1210 leukemia cells [8]. However, except for this and a report investigating the suitability of HCC cells as an in vitro model for the study of albendazole metabolism [9], no other report concerning the possible antitumor effect of BZs has appeared in literature. This coupled with our experience with these drugs [1], [10] and the fact that to date, there are very limited chemotherapeutic options available for the treatment of HCC [11], [12], led to the design of the current study. The study was undertaken to test the effect of albendazole, the most commonly used of the BZs, on cell proliferation rates, cell viability, cell cycle kinetics and the in vivo effects of the drug on xenografts in nude mice.
Section snippets
Cell culture
HepG2, Hep3-B, Hep1-6, SKHEP-1, PLC/PRF/5, and HTC cells were obtained from European Collection of Cell Cultures (ECACC; U.K.). Novikoff was obtained from Cancer Research Centre (DKFZ) Heidelberg, Germany. Cells were cultured in MEM or DMEM supplemented with 10% FBS, 50 units/ml penicillin, 50 units/ml streptomycin, 25 μg/ml amphotericin B (Gibco, Grand Island, NY) and maintained subconfluent at 37°C in humidified incubators containing 5% CO2. Albendazole (Sigma, Australian subsidiary) was
Inhibition of [3H]thymidine incorporation by albendazole
[3H]Thymidine incorporation assay was used to determine the effect of albendazole on cell proliferation in a number of human (HepG2, Hep3-B, PLC/PRF/5, SKHEP-1), rat (HTC and Novikoff) and mice (Hep1-6) HCC cell lines. Results obtained show that, in all cell lines examined, albendazole effectively reduces thymidine incorporation (Table 1). When treated with the 100 nM concentration of albendazole, compared to other cell lines, SKHEP-1 demonstrated the highest level of sensitivity to albendazole
Discussion
Albendazole is a drug that has been in use in the clinic for nearly two decades as the treatment of choice in a number of parasitic diseases. However, the mechanisms of action described for the drug suggest that, it may hold greater potential than it is currently employed for. To explore this possibility, we set out testing the drug against a range of HCC cell lines under both in vitro and in vivo conditions.
Results from the cell proliferation studies clearly demonstrated that all human, rat
References (27)
- et al.
The efficacy of treatment with albendazole
Acta Trop.
(1991) - et al.
Interaction of anthelmintic benzimidazoles and benzimidazole derivatives with bovine brain tubulin
Biochem. Biophys. Acta
(1978) - et al.
The interaction of benzimidazole carbamates with mammalian microtubule protein
Biochem. Pharmacol.
(1979) - et al.
The binding and subsequent inhibition of tubulin polymerization in Ascaris suum (in vitro) by benzimidazole anthelmintics
Biochem. Pharmacol.
(1984) - et al.
Structure-activity relationships of benzimidazole carbamates as inhibitors of mammalian tubulin, in vitro
Biochem. Pharmacol.
(1985) - et al.
Activity of benzimidazole carbamates against L1210 mouse leukaemia cells: correlation with in vitro tubulin polymerization assay
Biochem. Pharmacol.
(1985) Towards global control of liver cancer?
Semin. Cancer Biol.
(1998)- et al.
In vitro and in vivo inhibition of liver cancer cells by 1, 25-Dihydroxyvitamin D3
Cancer Lett.
(2000) - et al.
Paclitaxel shows cytotoxic activity in human hepatocellular carcinoma cell lines
Cancer Lett.
(1999) The role of the cytoskeletal protein, tubulin, in the mode of action and mechanism of drug resistance to benzimidazoles I
J. Parasitol.
(1988)